ABSTRACT
·
AIM:
To evaluate the
efficacy of anti -
vascular endothelial growth factor (
VEGF) and
photodynamic therapy (PDT) on
pathological myopia (PM) combined with
choroidal neovascularization (CNV). ·
METHODS:
Forty-three
patients (45
eyes) diagnosed by fundus
fluorescein angiography (FFA),
indocyanine green angiography ( ICGA ) and
optical coherence tomography (OCT) with PM combined with macular CNV were recruited in this study. The
patients were randomly divided into two groups for different
treatments,
intravitreal injection with
Ranibizumab (20
patients, 22
eyes) and PDT(23
patients,23
eyes).
After treatment,all
patients had been followed up monthly for 12mo. The further
treatments were operated according to
referral situations. The best corrected
visual acuity (BCVA) was recorded with the ETDRS chart and the mean defect(MD) of the center 10°
visual field was measured. At the last follow-up,the
therapy efficacy was determined by ETDRS numbers and MD and analyzed. ·
RESULTS:
Before
treatment, there was no significant difference on the baseline in ETDRS and MD between
ranibizumab group and PDT group (P>0.05). After 12mo
treatment, the ETDRS number in
ranibizumab group (39.23±20.06) significantly increased (by 5.88 ± 9.03, P<0.05), but the PDT group (37. 38 ± 16. 95) was not significantly improved(by 0.33±6.94,P>0.05). The MD in
ranibizumab group decreased significantly (P<0.05), and no significant change was found in PDT group(P>0.05). ·
CONCLUSION:
In the
treatment of macular CNV complicated by the PM,
ranibizumab injection can improve visual function better than PDT.